dr daniel landau presents calquence long-term and pooled cardiovascular safety data for cll/sll
Published 2 years ago • 16K plays • Length 27:13Download video MP4
Download video MP3
Similar videos
-
14:09
calquence® (acalabrutinib) safety data – dr levy, md
-
17:23
calquence® (acalabrutinib) pooled safety analysis – dr pinilla-lbarz, md
-
15:59
calquence® (acalabrutinib) long-term data – dr brem, md
-
11:22
eha25 virtual congress - calquence® trial results for chronic lymphocytic leukemia
-
3:35
dan’s story
-
2:18
how calquence® (acalabrutinib) works
-
12:20
calquence® (acalabrutinib) perspectives: dr alexey danilov, md, phd
-
10:34
calquence® (acalabrutinib) patient testimonials :doreen’s story
-
11:27
calquence® (acalabrutinib) perspectives: dr tara graff, do
-
19:00
calquence® (acalabrutinib) elevate-rr and ascend data – dr ma, md
-
1:19
real-world outcomes of liso-cel therapy in r/r dlbcl
-
5:35
evolution of biological understandings in cll
-
2:54
clonoseq: evaluating mrd in cll
-
9:12
treatment for cytogenetic-related outcomes in cll
-
1:39
current and future treatment strategies for cll
-
1:59
answers from the experts: long term expectations with alcl
-
3:46
utility of mrd testing in cll management
-
1:56
john leonard, m.d.
-
3:32
cll and covid-19: patient outcomes